Table 1 The clinicopathologic characteristics of patients in the training and validation cohorts

Gender: female/male (n)

48/322

21/125

0.104

Age (years)

51.74 ± 11.77

50.78 ± 10.89

0.261

HBsAg: negative/positive (n)

54/306

28/118

0.248

Family history: absent/present (n)

332 /38

124/22

0.126

Drinking: absent/present (n)

212/158

75/71

0.222

Smoking: absent/present (n)

218/152

88/58

0.778

Cirrhosis: absent/present (n)

34/336

11/135

0.548

MVI: absent/present (n)

280/90

117/29

0.279

NEUT (×10⁹/L)

3.90 ± 1.93

4.10 ± 2.36

0.436

LYMPH (×10⁹/L)

1.69 ± 0.61

1.66 ± 0.62

0.057

Platelets (×10⁹/L)

186.33 ± 86.03

183.56 ± 78.82

<  0.001*

GGT (U/L)

106.97 ± 120.92

104.40 ± 109.25

<  0.001*

LDH (U/L)

215.43 ± 95.46

204.79 ± 90.36

0.113

Tumor size (cm)

7.65 ± 4.54

7.97 ± 4.84

0.140

Tumor number: single/multiple (n)

280/50

108/38

0.239

Grade: G1/G2/G3 (n)

54/211/105

27/100/19

<  0.001*

LNM: absent/present (n)

10/360

7/139

0.230

Child-Pugh stage: A/B (n)

328/42

131/15

0.725

AFP ≤ 20/ > 20 (ng/mL)

130/240

53/93

<  0.001*

NLR

2.63 ± 2.17

2.81 ± 2.01

0.028*

GLR

74.86 ± 99.5

73.51 ± 82.8

0.115

GMWG

23.50 ± 12.32

23.6 ± 12.06

0.301